Skip to content

The Science of Adaptive Resistance: clinical-protocol and operator-economics review.

Free 45-minute webinar with live Q&A.

Next session: TBD — register to be notified.

What you'll learn

Peer-reviewed evidence

Adaptive-resistance and accentuated-eccentric-loading literature: dose-response, time-on-machine, lean-mass preservation, GLP-1 cohort.

Operator economics

Revenue per square foot, member-economics, the 100-client model and where ARX integrates into existing service-line P&L.

Reference installations

Site walkthroughs from clinical and business operators currently running ARX, with the integration choices they made.

Live Q&A with an ARX product specialist

Bring clinical-protocol or operator-fit questions specific to your facility.

Underlying evidence covered in the webinar

  • Dalleck 2021 RCT: Equivalent strength gains in less than half the time-on-machine vs. conventional resistance training.(verification pending)
  • AEL meta-analysis: Accentuated-eccentric loading drives greater hypertrophy and strength adaptation per session than concentric-only protocols.(verification pending)
  • GLP-1 muscle-loss cohort: Adaptive resistance preserves lean mass during GLP-1 weight loss when other modalities can't reach the dose-response threshold.(verification pending)
  • Time-efficiency studies: Two 15-minute sessions per week reach the strength dose-response threshold required for clinical outcomes.(verification pending)
  • Nuzzo 2023 CARE framework: The eccentric phase of adaptive resistance is mechanistically distinct from concentric-only loading; the dose-response advantage compounds across joint integrity, hypertrophy and strength.(verification pending)
  • Once-Weekly Eccentric protocol: Once-weekly eccentric protocols reach the dose-response threshold that conventional 3x/week routines target — the time-efficiency story for HNW and busy clinical buyers.(verification pending)
  • Oldest-old strength outcomes: Adaptive resistance produces meaningful strength and balance gains in the 80+ cohort where fall-prevention ROI is most measurable on incident rates and downstream care costs.(verification pending)
  • JAMA Network Open GLP-1 muscle loss: Patients on semaglutide / tirzepatide retain lean mass at meaningfully lower rates than non-GLP-1 weight-loss cohorts; structured resistance is the documented mitigation.(verification pending)
  • Galiano 2024 sarcopenia review: Resistance-based intervention slows sarcopenia progression in HRT-cohort patients; bone density outcomes correlate with adherence to dose-response strength protocols.(verification pending)
  • Delphi Consensus — longevity protocols: Expert consensus on the role of dose-response resistance training in longevity protocols — the strength dose is the consensus floor under which other longevity interventions underperform.(verification pending)
  • Resistance training & mortality: Sustained resistance training is independently associated with reduced all-cause mortality; the time-efficient delivery model preserves the effect at lower compliance burden.(verification pending)
  • Mayo clinical adoption white paper: Clinical adoption framework documents reimbursement-pathway and operator-economics models for adaptive resistance integration in integrated medical practice.(verification pending)

Register